5-fluorouracil + interleukin-2 + levofolinic acid

This is a combination regimen consisting of three agents: - **5-fluorouracil (5-FU):** A pyrimidine analog antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis and leading to cell death in rapidly dividing cells. - **Interleukin-2 (IL-2):** A cytokine immunotherapy that stimulates the proliferation and activation of T lymphocytes and natural killer (NK) cells, enhancing immune-mediated tumor cell killing. - **Levofolinic acid (levoleucovorin):** The active enantiomer of folinic acid; it enhances the binding of 5-FU to thymidylate synthase, increasing its cytotoxicity against cancer cells. This combination has been studied as a salvage or second-line treatment for metastatic colorectal carcinoma refractory to previous chemotherapy. The addition of low-dose IL-2 aims to boost immune response without significantly increasing toxicity. Levofolinic acid potentiates the effect of 5-FU by stabilizing its binding to thymidylate synthase[1][6][8].

Other names

5-FU + IL-2 + levofolinic acidfluorouracil + recombinant interleukin-2 + levoleucovorin5-fluorouracil + rIL-2 + levoleucovorin